Mechanism · Research Data · Regulatory Status · Compound Information
Melanotan II is a lab-made peptide that darkens skin without sun exposure, but it isn't approved by any medicines regulator anywhere, for any use. It works by switching on several receptors at once, which is exactly why it can also affect libido and appetite alongside tanning; that lack of selectivity is also why it was later refined into a separate, more targeted drug called PT-141 for female sexual dysfunction. Because it only circulates through unregulated grey-market suppliers, most of what's known about its real-world harms comes from case reports rather than proper clinical trials, including new or changing moles and, in some injectable users, kidney injury. There's no dosing information on this page because there's no licensed product or protocol to reference.
Melanotan II (MT-II) is a synthetic cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH). It is a non-selective melanocortin receptor agonist, meaning it activates multiple melanocortin receptor subtypes at once — MC1R, MC3R, and MC4R — rather than targeting one selectively.
Melanotan II is not approved by any medicines regulator anywhere in the world for any indication. It is not approved by the FDA, not approved by the EMA, and not approved by Ireland's Health Products Regulatory Authority (HPRA). It has no licensed medicinal use. In practice, it circulates almost exclusively through unregulated, grey-market and black-market channels, most commonly marketed informally as an injectable "tanning" product and, less commonly, for its libido-related effects. Nothing in this guide should be read as an endorsement of its use — the purpose here is to document what has actually been studied and what is known about its risks.
Melanotan II's clinical relevance today is largely historical: it was the parent research compound from which a more receptor-selective, regulator-reviewed molecule — PT-141 (bremelanotide) — was later derived and refined for the treatment of hypoactive sexual desire disorder (HSDD) in women. That refinement effort happened specifically because Melanotan II's non-selective receptor activity was considered too broad and too unpredictable for pharmaceutical development.
| Status | Finding |
|---|---|
| Regulatory Approval (FDA/EMA/HPRA) | ✗ Not approved anywhere, for any indication |
| Human RCT Data | Limited — early-phase pilot studies only (1990s), not registration trials |
| In Vitro Studies | ✔ Receptor-binding and pharmacology characterised |
| Animal Studies | ✔ Preclinical melanogenesis and behavioural studies |
| Market Status in Ireland/EU | Unregulated — sold only via grey/black-market suppliers, not through licensed pharmacies |
| Successor Compound | PT-141 / bremelanotide — MC4R-selective derivative, later studied for HSDD |
Melanotan II is a broad, non-selective melanocortin receptor agonist. It activates MC1R on melanocytes, which drives melanogenesis — the production of melanin — producing skin darkening without the need for UV exposure. It simultaneously activates MC3R and MC4R in the hypothalamus, receptors that are part of the pathways linked to appetite regulation and sexual arousal.
This lack of receptor selectivity is the central mechanistic feature to understand: it is precisely why Melanotan II produces both a tanning effect (via MC1R) and a libido/arousal effect (via MC4R) in the same molecule, and it is also why its side-effect profile is broader and less predictable than more selective successor compounds. Bremelanotide (PT-141) was later developed specifically to isolate the MC4R-driven arousal effect while minimising the off-target MC1R and MC3R activity that contributes to Melanotan II's pigmentation changes and other effects.
Melanotan II's origins trace back to research at the University of Arizona under Mac E. Hadley and colleagues, who investigated melanotropic peptides as potential non-UV agents to induce melanogenesis — with an original research rationale centred on skin cancer prevention via increased natural pigmentation, rather than cosmetic tanning. The compound later leaked out of formal research channels into unregulated cosmetic and bodybuilding markets, where it is now used almost exclusively for its tanning effect, entirely outside any research or medical oversight.
Early human studies examined Melanotan II's effect on erectile function and sexual arousal in men, providing proof-of-concept evidence that melanocortin receptor activation could drive sexual arousal independent of the vascular mechanisms targeted by drugs like sildenafil. This work is historically significant because it directly informed the later development of bremelanotide (PT-141) as a more selective, better-tolerated molecule for HSDD.
MC3R and MC4R are established regulators of feeding behaviour and energy balance in preclinical models. Melanotan II's activity at these receptors has made it a reference tool compound in melanocortin pathway research, though this has not translated into any approved appetite-related therapeutic use.
Because Melanotan II is used almost exclusively outside regulated settings, much of what is known about its real-world risk comes from case reports rather than controlled trials. Dermatology and toxicology literature has documented concerns including new or changing pigmented lesions (raising melanoma surveillance concerns), and case reports describing acute kidney injury associated with unregulated injectable use. This is case-report-level evidence, not randomised trial data, and should be weighted accordingly — but it is consistent and recurring enough to be a genuine safety signal.
| Study / Source | Design | Key Finding |
|---|---|---|
| Dorr RT et al., 1996 (Life Sciences) | Pilot Phase I, human | First human evaluation of Melanotan-II; documented tanning and libido-related effects alongside nausea |
| Wessells H et al., 1998–2000 (Int. J. Impotence Research / J. Urology) | Human, proof-of-concept | Melanocortin receptor agonism linked to penile erection and sexual motivation in men — foundational work behind PT-141 development |
| Hadley ME & Dorr RT, 2006 (Peptides) | Review | Review of melanotropic peptide pharmacology and clinical development history |
| Dermatology/toxicology case reports (2010s) | Case report level | Reports of melanocytic lesion changes and acute kidney injury associated with unregulated injectable Melanotan II use |
⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance.
This site does not publish doses, durations or frequencies for any compound. Published research protocols for this compound vary considerably between studies in design, intensity and duration. Those details are not something to copy from a fitness website — anyone researching this compound should read the primary literature directly and talk to a doctor who knows their bloods.
Because Melanotan II has no approved medical use anywhere, there is no regulator-reviewed safety monitoring of any product sold as "Melanotan II." Anyone considering its use should be aware that documented case reports include serious events, and that product quality, dose accuracy, and contamination status cannot be verified for grey-market sources.
What is Melanotan II and how is it different from a normal tan?
Melanotan II is a synthetic peptide that activates melanocortin receptors (MC1R, MC3R, MC4R) to trigger melanin production. The tan it produces comes from stimulating the skin's own pigment-producing cells rather than UV exposure, which is also why it produces effects unrelated to tanning, such as changes in libido and appetite.
Is Melanotan II legal or regulated in Ireland?
No. Melanotan II is not approved by the HPRA, the EMA or the FDA for any use, including tanning. It has no licensed medicinal status anywhere and circulates only through unregulated grey and black market suppliers, which means purity, dose accuracy and contamination cannot be verified by any regulator.
What are the documented health risks of Melanotan II?
Case report literature has documented new or changing pigmented moles, a melanoma surveillance concern, prolonged or spontaneous erections including priapism, nausea, and in unregulated injectable use, reports of acute kidney injury. This is case-report-level evidence rather than randomised trial data, but it is a genuine and recurring safety signal.
Is Melanotan II related to the drug PT-141 (bremelanotide)?
Yes. Bremelanotide (PT-141) is a more receptor-selective molecule that was later developed from Melanotan II specifically because Melanotan II's broad, non-selective melanocortin activity was considered too unpredictable for pharmaceutical development. Bremelanotide went on to be studied for hypoactive sexual desire disorder (HSDD); Melanotan II itself never followed that pathway to approval.
This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.
Reconstitution calculator, dosing-frequency planner and cycle-length calculator. No signup required.
Open the Peptide CalculatorsTracking food too? Free calorie counter with barcode scanner →